The investigational drug afatinib increases progression-free survival but not overall survival in refractory nonsmall-cell lung cancer (NSCLC) with epidermal growth-factor receptor mutation. Medscape Medical News
Dr. Maurie Markman reviews a new study looking at the effect of TP53 mutations on outcomes after fludarabine-based chemotherapy in patients with chronic lymphocytic leukemia. Medscape Genomic Medicine